Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
69.61
-1.12 (-1.58%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
The Importance of Self Advocacy in Breast Cancer: Janelle's Story
November 23, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Product Recall
Exposures
Legal
Product Safety
Gilead Submits Biologics License Application to U.S. Food and Drug Administration for Bulevirtide, an Investigational Treatment for People Living With Chronic Hepatitis Delta
November 19, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conference
November 18, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration
November 18, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Commits to Electrifying Its Fleet
November 16, 2021
SOURCE: Gilead Sciences
Via
3BL Media
India's Efforts to Help End Hepatitis C Starts With Prison Population
November 18, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Death
Exposures
COVID-19
Death
Kerri Fitzpatrick Puts Patients Front and Center
November 12, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-Negative Breast Cancer Meets Primary Overall Response Rate Endpoint
November 10, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead to Present Data From Liver Disease Development Programs at The Liver Meeting®
November 09, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
BA Insight for Amazon OpenSearch Service and BA Insight for Amazon Kendra Available Immediately in AWS Marketplace
November 12, 2021
BOSTON - Nov. 12, 2021 - PRLog -- BA Insight has today announced availability of two Amazon Web Services Marketplace offerings: BA Insight for Amazon OpenSearch Service and BA Insight for Amazon...
Via
PRLog
Healthcare Nanotechnology (Nanomedicine) Market Next Big Thing : Gilead Sciences, Pfizer, 3M
November 10, 2021
The latest independent research document on Worldwide Healthcare Nanotechnology (Nanomedicine) examine investment in Market.
Via
SBWire
Thumbi Ndung'u on Thinking Beyond Lifelong Treatment in HIV
November 09, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Gilead and Kite Oncology Demonstrate Broad Leadership in Cell Therapy and Expanding Blood Cancer Pipeline
November 04, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
'Inside the Innovation:' Oncology Leaders Discuss Life at Gilead
November 02, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Clinical and Patient-Reported Outcomes in People Living With HIV on Biktarvy® in Observational BICSTaR Study Demonstrate Consistent Efficacy Profile in Real-World Setting
October 29, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Announces Clinical Trial Collaboration With Merck to Evaluate Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) in Patients With First-Line Metastatic Triple-Negative Breast Cancer
October 28, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces Third Quarter 2021 Financial Results
October 28, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Four Questions With Sade Clacken Joseph: Using Film As a Change Agent
October 26, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Religion
Exposures
Religion
Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults
October 26, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Global Parkinsons Disease Drugs Market Market Development Overview 2021:Johnson & Johnson, Gilead Sciences, Pacira
October 21, 2021
QY Research has made a brilliant attempt to elaborately and meticulously analyze the global Parkinsons Disease Drugs market in its latest report. All of the market forecasts presented in the report are...
Via
SBWire
Topics
Initial Public Offering
Exposures
Securities Market
Gilead Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Option for a Broad Range of People Living With HIV
October 21, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Putting Faith Into Conversations About HIV in the Southern United States
October 19, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Sciences Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia
October 19, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gene Therapy Market Worth $13.0 Billion by 2024 - Exclusive Report by MarketsandMarkets(TM)
October 20, 2021
Chicago, Illinois--(Newsfile Corp. - October 20, 2021) - According to the new market research report "Gene Therapy Market by Vectors...
Via
Newsfile
U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations
October 18, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer
October 15, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Release Third Quarter 2021 Financial Results on Thursday, October 28, 2021
October 14, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Interns Help Facilitate Breast Cancer Conversations Among Young Black Women
October 12, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Launches Pharmaceutical Education Program to Increase Workplace Diversity
October 05, 2021
SOURCE: Gilead Sciences
Via
3BL Media
U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
October 01, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.